rasagiline 0.5 MG Oral Tablet

1 INDICATIONS AND USAGE Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD). Rasagiline tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), are indicated for the treatment of Parkinson’s disease ( 1 )

Mylan Pharmaceuticals Inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] fatigue` `[3] pain` `[4] nausea` `[5] off label use` `[6] dyspnoea` `[7] diarrhoea` `[8] dizziness` `[9] headache` `[10] rash`

5 years ago

ROUND WHITE M RA 5

16 HOW SUPPLIED/STORAGE AND HANDLING Rasagiline Tablets are available containing 0.5 mg or 1 mg of rasagiline equivalent to 0.78 mg or 1.56 mg of rasagiline mesylate, respectively. The 0.5 mg tablets are white to off-white, round tablets debossed with M on one side of the tablet and RA over 5 on the other side. They are available as follows: NDC 0378-1270-93 bottles of 30 tablets The 1 mg tablets are white to off-white, round tablets debossed with M on one side of the tablet and RA over 1 on the other side. They are available as follows: NDC 0378-1271-93 bottles of 30 tablets Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

More pills like ROUND M RA 5

Related Pills

rasagiline 1 MG Oral Tablet

Mylan Pharmaceuticals Inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site